Poolbeg Pharma, a biopharmaceutical company based in Dublin, is in talks for a potential acquisition by Nasdaq-listed Hookipa Pharma. The announcement has led to a significant decline in Poolbeg's share price, which fell by 40% in London trading. The discussions for the acquisition were confirmed on January 2, 2025, amidst reports of a US tie-up led by Cathal Friel, the company's chairman. The news has drawn attention to the financial health of Poolbeg Pharma as the market reacts to the takeover talks.